KNSA

SEC source: 0000950170-25-082485 · ownership.xml · derivative · entry 6

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 50,394

Underlying: Class A Ordinary Shares · 50,394 shares

Expires 2035-06-02

F12 · shares: Includes 16,798 Share Options granted by the Issuer to each of Felix J. Baker, Dr. Biggar and M. Cantey Boyd on June 3, 2025, pursuant to the Incentive Award Plan. The Share Options have a strike price of $29.11 and vest in 12 equal monthly installments beginning on July 3, 2025 with the final installment vesting on the earlier of June 3, 2026 or the date of the next annual meeting of shareholder's of the Issuer, subject to the applicable director's continuous service on the Board through the vesting date. The Share Options expire 10 years from the date of grant.

F12 · derivative.exercise_date: Includes 16,798 Share Options granted by the Issuer to each of Felix J. Baker, Dr. Biggar and M. Cantey Boyd on June 3, 2025, pursuant to the Incentive Award Plan. The Share Options have a strike price of $29.11 and vest in 12 equal monthly installments beginning on July 3, 2025 with the final installment vesting on the earlier of June 3, 2026 or the date of the next annual meeting of shareholder's of the Issuer, subject to the applicable director's continuous service on the Board through the vesting date. The Share Options expire 10 years from the date of grant.

F3 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker, Dr. Biggar and M. Cantey Boyd do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified share options exercisable solely into Class A Ordinary Shares ("Share Options") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Share Options, RSUs and any Class A Ordinary Shares acquired upon the exercise of Share Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service.

F4 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F5 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F6 · ownership.nature: Pursuant the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any Class A Ordinary Shares received as a result of the exercise of Share Options or vesting of RSUs.

F7 · ownership.nature: The acquisitions of the RSUs and Share Options reported on this form represent grants to each of Felix J. Baker, Dr. Biggar and M. Cantey Boyd of 2,799 RSUs on Table I and 16,798 Share Options on Table II. These grants, totaling 8,397 RSUs and 50,394 Share Options for Felix J. Baker, Dr. Biggar and M. Cantey Boyd in the aggregate, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F9 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Class A Ordinary Shares reported in column 5 of Table I and the Share Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-25-082485 · ownership.xml · derivative · entry 5

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 50,394

Underlying: Class A Ordinary Shares · 50,394 shares

Expires 2035-06-02

F12 · shares: Includes 16,798 Share Options granted by the Issuer to each of Felix J. Baker, Dr. Biggar and M. Cantey Boyd on June 3, 2025, pursuant to the Incentive Award Plan. The Share Options have a strike price of $29.11 and vest in 12 equal monthly installments beginning on July 3, 2025 with the final installment vesting on the earlier of June 3, 2026 or the date of the next annual meeting of shareholder's of the Issuer, subject to the applicable director's continuous service on the Board through the vesting date. The Share Options expire 10 years from the date of grant.

F12 · derivative.exercise_date: Includes 16,798 Share Options granted by the Issuer to each of Felix J. Baker, Dr. Biggar and M. Cantey Boyd on June 3, 2025, pursuant to the Incentive Award Plan. The Share Options have a strike price of $29.11 and vest in 12 equal monthly installments beginning on July 3, 2025 with the final installment vesting on the earlier of June 3, 2026 or the date of the next annual meeting of shareholder's of the Issuer, subject to the applicable director's continuous service on the Board through the vesting date. The Share Options expire 10 years from the date of grant.

F2 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Class A Ordinary Shares reported in column 5 of Table I and the Share Options (as defined below) reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker, Dr. Biggar and M. Cantey Boyd do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified share options exercisable solely into Class A Ordinary Shares ("Share Options") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Share Options, RSUs and any Class A Ordinary Shares acquired upon the exercise of Share Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service.

F4 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F5 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F6 · ownership.nature: Pursuant the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any Class A Ordinary Shares received as a result of the exercise of Share Options or vesting of RSUs.

F7 · ownership.nature: The acquisitions of the RSUs and Share Options reported on this form represent grants to each of Felix J. Baker, Dr. Biggar and M. Cantey Boyd of 2,799 RSUs on Table I and 16,798 Share Options on Table II. These grants, totaling 8,397 RSUs and 50,394 Share Options for Felix J. Baker, Dr. Biggar and M. Cantey Boyd in the aggregate, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

SEC source: 0000950170-25-082485 · ownership.xml · nonDerivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,738,816

F1 · shares: Includes 2,799 restricted share units (each an "RSU") payable solely in Class A ordinary shares ("Class A Ordinary Shares") granted by Kiniksa Pharmaceuticals International, plc. (the "Issuer") to each of Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP"), and Dr. Stephen R. Biggar and M. Cantey Boyd, employees of Baker Bros. Advisors LP (the "Adviser"), on June 3, 2025, pursuant to the Issuer's 2018 Incentive Award Plan, as amended (the "Incentive Award Plan"). The RSUs fully vest on the earlier of June 3, 2026 or the date of the next annual meeting of shareholder's of the Issuer, subject to the applicable director's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Felix J. Baker, Dr. Biggar and M. Cantey Boyd serve on the Board as representatives of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F3 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker, Dr. Biggar and M. Cantey Boyd do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified share options exercisable solely into Class A Ordinary Shares ("Share Options") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Share Options, RSUs and any Class A Ordinary Shares acquired upon the exercise of Share Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service.

F4 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F5 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F6 · ownership.nature: Pursuant the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any Class A Ordinary Shares received as a result of the exercise of Share Options or vesting of RSUs.

F7 · ownership.nature: The acquisitions of the RSUs and Share Options reported on this form represent grants to each of Felix J. Baker, Dr. Biggar and M. Cantey Boyd of 2,799 RSUs on Table I and 16,798 Share Options on Table II. These grants, totaling 8,397 RSUs and 50,394 Share Options for Felix J. Baker, Dr. Biggar and M. Cantey Boyd in the aggregate, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F8 · ownership.nature: Includes beneficial ownership of 12,546 Class A Ordinary Shares received from vested RSUs each previously granted to Felix J. Baker and Dr. Biggar and 4,730 Class A Ordinary Shares received from vested RSUs previously granted to M. Cantey Boyd, in their capacity as directors of the Issuer.

F9 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Class A Ordinary Shares reported in column 5 of Table I and the Share Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-25-082485 · ownership.xml · nonDerivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 137,199

F1 · shares: Includes 2,799 restricted share units (each an "RSU") payable solely in Class A ordinary shares ("Class A Ordinary Shares") granted by Kiniksa Pharmaceuticals International, plc. (the "Issuer") to each of Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP"), and Dr. Stephen R. Biggar and M. Cantey Boyd, employees of Baker Bros. Advisors LP (the "Adviser"), on June 3, 2025, pursuant to the Issuer's 2018 Incentive Award Plan, as amended (the "Incentive Award Plan"). The RSUs fully vest on the earlier of June 3, 2026 or the date of the next annual meeting of shareholder's of the Issuer, subject to the applicable director's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Felix J. Baker, Dr. Biggar and M. Cantey Boyd serve on the Board as representatives of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F2 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Class A Ordinary Shares reported in column 5 of Table I and the Share Options (as defined below) reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker, Dr. Biggar and M. Cantey Boyd do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified share options exercisable solely into Class A Ordinary Shares ("Share Options") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Share Options, RSUs and any Class A Ordinary Shares acquired upon the exercise of Share Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service.

F4 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F5 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F6 · ownership.nature: Pursuant the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any Class A Ordinary Shares received as a result of the exercise of Share Options or vesting of RSUs.

F7 · ownership.nature: The acquisitions of the RSUs and Share Options reported on this form represent grants to each of Felix J. Baker, Dr. Biggar and M. Cantey Boyd of 2,799 RSUs on Table I and 16,798 Share Options on Table II. These grants, totaling 8,397 RSUs and 50,394 Share Options for Felix J. Baker, Dr. Biggar and M. Cantey Boyd in the aggregate, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F8 · ownership.nature: Includes beneficial ownership of 12,546 Class A Ordinary Shares received from vested RSUs each previously granted to Felix J. Baker and Dr. Biggar and 4,730 Class A Ordinary Shares received from vested RSUs previously granted to M. Cantey Boyd, in their capacity as directors of the Issuer.

SEC source: 0001415889-25-015778 · form4-06052025_080632.xml · derivative · entry 3

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Share · 18,299 shares

Expires 2028-05-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.

F2 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001415889-25-015778 · form4-06052025_080632.xml · nonDerivative · entry 2

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,009

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.

SEC source: 0001415889-25-015778 · form4-06052025_080632.xml · nonDerivative · entry 1

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,308

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.

SEC source: 0001415889-25-015805 · form4-06052025_090634.xml · derivative · entry 3

Cole G Bradley · CIK 0001337798 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,799

Underlying: Class A Ordinary Shares · 2,799 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

F3 · derivative.exercise_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025.

F3 · derivative.expiration_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025.

SEC source: 0001415889-25-015805 · form4-06052025_090634.xml · derivative · entry 2

Cole G Bradley · CIK 0001337798 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,798

Underlying: Class A Ordinary Shares · 16,798 shares

Expires 2035-06-02

F2 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025.

SEC source: 0001415889-25-015800 · form4-06052025_090611.xml · derivative · entry 3

Levy Richard S · CIK 0001454983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,799

Underlying: Class A Ordinary Shares · 2,799 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

F3 · derivative.exercise_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025.

F3 · derivative.expiration_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025.

SEC source: 0001415889-25-015800 · form4-06052025_090611.xml · derivative · entry 2

Levy Richard S · CIK 0001454983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,798

Underlying: Class A Ordinary Shares · 16,798 shares

Expires 2035-06-02

F2 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025.

SEC source: 0001415889-25-015796 · form4-06052025_090659.xml · derivative · entry 4

Malley Thomas · CIK 0001403322 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,799

Underlying: Class A Ordinary Shares · 2,799 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

F4 · derivative.exercise_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025.

F4 · derivative.expiration_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025.

SEC source: 0001415889-25-015796 · form4-06052025_090659.xml · derivative · entry 3

Malley Thomas · CIK 0001403322 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,798

Underlying: Class A Ordinary Shares · 16,798 shares

Expires 2035-06-02

F3 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025.

SEC source: 0001415889-25-015792 · form4-06052025_080654.xml · derivative · entry 3

McCain Tracey L · CIK 0001683600 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,799

Underlying: Class A Ordinary Shares · 2,799 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

F3 · derivative.exercise_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025.

F3 · derivative.expiration_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025.

SEC source: 0001415889-25-015792 · form4-06052025_080654.xml · derivative · entry 2

McCain Tracey L · CIK 0001683600 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,798

Underlying: Class A Ordinary Shares · 16,798 shares

Expires 2035-06-02

F2 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025.

SEC source: 0001415889-25-015784 · form4-06052025_080657.xml · derivative · entry 3

Quart Barry D · CIK 0001384243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,799

Underlying: Class A Ordinary Shares · 2,799 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

F3 · derivative.exercise_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025.

F3 · derivative.expiration_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025.

SEC source: 0001415889-25-015784 · form4-06052025_080657.xml · derivative · entry 2

Quart Barry D · CIK 0001384243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,798

Underlying: Class A Ordinary Shares · 16,798 shares

Expires 2035-06-02

F2 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025.

SEC source: 0001415889-25-015788 · form4-06052025_080613.xml · derivative · entry 3

Popovits Kimberly J · CIK 0001333482 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,799

Underlying: Class A Ordinary Shares · 2,799 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

F3 · derivative.exercise_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025.

F3 · derivative.expiration_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025.

SEC source: 0001415889-25-015788 · form4-06052025_080613.xml · derivative · entry 2

Popovits Kimberly J · CIK 0001333482 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,798

Underlying: Class A Ordinary Shares · 16,798 shares

Expires 2035-06-02

F2 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025.

SEC source: 0001415889-25-015782 · form4-06052025_080606.xml · derivative · entry 3

Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 791

Underlying: Class A Ordinary Share · 15,211 shares

Expires 2030-09-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001415889-25-015782 · form4-06052025_080606.xml · nonDerivative · entry 2

Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,546

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024.

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $28.75 and $28.755. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-25-015782 · form4-06052025_080606.xml · nonDerivative · entry 1

Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,757

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024.

SEC source: 0001415889-25-015780 · form4-06052025_080613.xml · derivative · entry 3

Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Share · 27,594 shares

Expires 2029-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on November 13, 2024.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001415889-25-015780 · form4-06052025_080613.xml · nonDerivative · entry 2

Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,415

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on November 13, 2024.

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $29.00 and $29.115. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-25-015780 · form4-06052025_080613.xml · nonDerivative · entry 1

Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,009

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on November 13, 2024.

SEC source: 0001415889-25-014744 · form4-05282025_050501.xml · derivative · entry 10

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Share · 62,116 shares

Expires 2025-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001415889-25-014744 · form4-05282025_050501.xml · nonDerivative · entry 6

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 96,674

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $27.00 and $27.76. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-25-014744 · form4-05282025_050501.xml · nonDerivative · entry 5

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 158,790

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

SEC source: 0001415889-25-014744 · form4-05282025_050501.xml · derivative · entry 9

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 62,116

Underlying: Class A Ordinary Share · 19,317 shares

Expires 2025-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001415889-25-014744 · form4-05282025_050501.xml · nonDerivative · entry 4

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 96,674

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $27.00 and $27.06. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-25-014744 · form4-05282025_050501.xml · nonDerivative · entry 3

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 115,991

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

SEC source: 0001415889-25-014744 · form4-05282025_050501.xml · derivative · entry 8

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 81,433

Underlying: Class A Ordinary Share · 4,837 shares

Expires 2025-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001415889-25-014744 · form4-05282025_050501.xml · nonDerivative · entry 2

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 96,674

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $27.00 and $27.03. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-25-014744 · form4-05282025_050501.xml · nonDerivative · entry 1

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 101,511

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

SEC source: 0001415889-25-014167 · form4-05222025_080524.xml · derivative · entry 4

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 86,270

Underlying: Class A Ordinary Share · 2,349 shares

Expires 2025-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001415889-25-014167 · form4-05222025_080524.xml · nonDerivative · entry 2

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 96,674

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $27.00 and $27.04. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-25-014167 · form4-05222025_080524.xml · nonDerivative · entry 1

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 99,023

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

SEC source: 0001415889-25-013944 · form4-05212025_080502.xml · derivative · entry 3

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49

Underlying: Class A Ordinary Share · 7,000 shares

Expires 2027-06-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001415889-25-013944 · form4-05212025_080502.xml · nonDerivative · entry 2

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 72,363

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $25.975 and $26.76. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-25-013944 · form4-05212025_080502.xml · nonDerivative · entry 1

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 84,363

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.

SEC source: 0001415889-25-013170 · form4-05152025_080533.xml · derivative · entry 4

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 88,619

Underlying: Class A Ordinary Share · 2,872 shares

Expires 2025-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001415889-25-013170 · form4-05152025_080533.xml · nonDerivative · entry 2

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 96,674

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $27.00 and $27.06. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-25-013170 · form4-05152025_080533.xml · nonDerivative · entry 1

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 99,546

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

SEC source: 0001415889-25-012571 · form4-05092025_090511.xml · derivative · entry 10

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 91,491

Underlying: Class A Ordinary Share · 6,029 shares

Expires 2025-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001415889-25-012571 · form4-05092025_090511.xml · nonDerivative · entry 6

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 96,674

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $27.03 and $27.14. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-25-012571 · form4-05092025_090511.xml · nonDerivative · entry 5

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 102,703

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

SEC source: 0001415889-25-012571 · form4-05092025_090511.xml · derivative · entry 9

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 97,520

Underlying: Class A Ordinary Share · 101 shares

Expires 2025-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001415889-25-012571 · form4-05092025_090511.xml · nonDerivative · entry 4

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 96,674

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

SEC source: 0001415889-25-012571 · form4-05092025_090511.xml · nonDerivative · entry 3

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 96,775

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

SEC source: 0001415889-25-012541 · form4-05092025_090502.xml · derivative · entry 3

Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 65,867

Underlying: Class A Ordinary Share · 200 shares

Expires 2027-06-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2024.

F2 · derivative.exercise_date: The option is fully vested and exercisable.